[Federal Register Volume 76, Number 52 (Thursday, March 17, 2011)]
[Notices]
[Pages 14689-14690]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-6157]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 9, 2010,
Mallinckrodt, Inc., 3600 North Second Street, St. Louis, Missouri
63147, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)................ I
Codeine-N-oxide (9053)...................... I
Dihydromorphine (9145)...................... I
Difenoxin (9168)............................ I
Morphine-N-oxide (9307)..................... I
Normorphine (9313).......................... I
Norlevorphanol (9634)....................... I
Amphetamine (1100).......................... II
Methamphetamine (1105)...................... II
Methylphenidate (1724)...................... II
Nabilone (7379)............................. II
Codeine (9050).............................. II
Diprenorphine (9058)........................ II
Etorphine HCl (9059)........................ II
[[Page 14690]]
Dihydrocodeine (9120)....................... II
Oxycodone (9143)............................ II
Hydromorphone (9150)........................ II
Diphenoxylate (9170)........................ II
Ecgonine (9180)............................. II
Hydrocodone (9193).......................... II
Levorphanol (9220).......................... II
Meperidine (9230)........................... II
Methadone (9250)............................ II
Methadone intermediate (9254)............... II
Metopon (9260).............................. II
Dextropropoxyphene, bulk (9273)............. II
Morphine (9300)............................. II
Oripavine (9330)............................ II
Thebaine (9333)............................. II
Opium extracts (9610)....................... II
Opium fluid extract (9620).................. II
Opium tincture (9630)....................... II
Opium, powdered (9639)...................... II
Opium, granulated (9640).................... II
Levo-alphacetylmethadol (9648).............. II
Oxymorphone (9652).......................... II
Noroxymorphone (9668)....................... II
Alfentanil (9737)........................... II
Remifentanil (9739)......................... II
Sufentanil (9740)........................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The firm plans to manufacture the listed controlled substances for
internal use and for sale to other companies.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than May 16, 2011.
Dated: March 9, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-6157 Filed 3-16-11; 8:45 am]
BILLING CODE 4410-09-P